Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
3.950
-0.011 (-0.28%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focused on accelerating the clinical development programs of novel and disruptive therapeutic assets.
The company is developing SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers.
Medicus Pharma Ltd. was founded in 2015 and is headquartered in Toronto, Canada.
Medicus Pharma Ltd.
| Country | Canada |
| Founded | 2008 |
| Industry | Other |
| CEO | Raza Bokhari |
Contact Details
Address: One First Canadian Place, Suite 3400 Toronto, ON M5X 1A4 Canada | |
| Phone | 610-636-0184 |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| Employer ID | 98-1778211 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raza Bokhari | Chief Executive Officer |
| James Quinlan | Chief Financial Officer |
| Viktoriia Slepeniuk | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 10, 2025 | QUALIF | Filing |
| Apr 4, 2025 | 1-A POS | Filing |
| Apr 4, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 2, 2025 | QUALIF | Filing |
| Mar 28, 2025 | 1-A POS | Filing |
| Mar 28, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 8-K | Current Report |